In Vivo Angiostatin Generation Using Tissue Plasminogen Activator and Captopril in Treating Patients With Progressive Metastatic Cancer

Unspecified Adult Solid Tumor, Protocol Specific Clinical Trial

Official title:

Phase I/II Trial of In Vivo Angiostatin Generation With Tissue Plasminogen Activator (tPA) and Captopril in Patients With Progressive, Metastatic Cancer

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00086723
• Other study ID #: NCI 00B9
• Secondary ID: NU-NCI-00B9
• Status: Completed
• Phase: Phase 1/Phase 2
• First received: July 8, 2004
• Last updated: June 7, 2012
• Start date: July 2003
• Est. completion date: January 2006

Study information

• Verified date: June 2012
• Source: Northwestern University
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Federal Government
• Study type: Interventional

Clinical Trial Summary

RATIONALE: Tissue plasminogen activator and captopril may help the body generate angiostatin. Angiostatin may stop the growth of cancer by stopping blood flow to the tumor.

PURPOSE: This phase I/II trial is studying the side effects and best dose of tissue plasminogen activator and captopril and to see how well they work in treating patients with progressive metastatic cancer.

Description:

OBJECTIVES:

Primary

• Determine the maximum tolerated dose and toxicity of captopril and tissue plasminogen activator (tPA) in patients with progressive metastatic cancer.

• Determine the in vivo generation of angiostatin by western analysis in patients treated with this regimen.

Secondary

• Determine the antitumor effect of this regimen in these patients.

OUTLINE: This is a dose-escalation study.

Patients receive tissue plasminogen activator (tPA) IV over 6 hours and oral captopril twice daily on days 1-5. Courses repeat every 14 days for up to 1 year in the absence of disease progression or unacceptable toxicity. Patients who achieve a complete response (CR) receive 2 additional courses beyond CR.

Cohorts of 3-6 patients receive escalating doses of tPA and captopril until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.

PROJECTED ACCRUAL: Not specified.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 0
• Est. completion date: January 2006
• Est. primary completion date: January 2006
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

DISEASE CHARACTERISTICS:

• Diagnosis of progressive metastatic cancer, excluding hematologic malignancies (i.e., leukemia or lymphoma)

• Measurable disease not required

• Must have received at least 1 prior systemic treatment for metastatic disease

• No known CNS involvement

• CNS involvement allowed provided it is successfully controlled by prior surgery or radiotherapy and there is no current requirement for corticosteroids

PATIENT CHARACTERISTICS:

Age

• 18 and over

Performance status

• ECOG 0-2

Life expectancy

• At least 3 months

Hematopoietic

• Granulocyte count at least 1,500/mm^3

• Platelet count at least 100,000/mm^3

• No bleeding diathesis

Hepatic

• Bilirubin no greater than 1.5 mg/dL

• SGOT no greater than 3 times upper limit of normal

• Albumin normal

• PT and aPTT normal

• Fibrinogen > lower limit of normal

Renal

• Creatinine no greater than 1.8 mg/dL

Cardiovascular

• No myocardial infarction within the past 6 months

• No history of stroke, transient ischemic attack, or symptoms of cerebral ischemia

• No history of angioedema with captopril

• No severe or uncontrolled hypertension (i.e., systolic blood pressure greater than 180 mm Hg or diastolic blood pressure greater than 110 mm Hg)

• No congestive heart failure requiring therapy

• No chronic hypotension (e.g., systolic blood pressure less than 100 mm Hg)

Other

• Not pregnant or nursing

• Fertile patients must use effective contraception

• HIV negative

• Potassium no greater than 5.2 mmol/L

• No active internal bleeding

• No history of seizures

• No psychiatric disorder that would preclude the giving of informed consent or study follow-up

• No other malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer or carcinoma in situ of the cervix

• No uncontrolled or active bacterial, viral, or invasive fungal infection

• No recent trauma

• No medical indication for anticoagulation

• No contraindication to captopril

PRIOR CONCURRENT THERAPY:

Biologic therapy

• At least 4 weeks since prior biologic therapy

• No concurrent immunomodulator therapy

Chemotherapy

• At least 4 weeks since prior chemotherapy

• No concurrent chemotherapy

Endocrine therapy

• See Disease Characteristics

• At least 4 weeks since prior endocrine therapy

Radiotherapy

• See Disease Characteristics

• At least 4 weeks since prior radiotherapy

Surgery

• See Disease Characteristics

• No recent intracranial or intraspinal surgery

• No concurrent surgery

Other

• More than 48 hours since prior anticoagulation agents (e.g., warfarin or heparin)

• More than 3 weeks since prior investigational agents

• No concurrent anticoagulation agents, aspirin, or nonsteroidal anti-inflammatory drugs

• No other concurrent investigational agent

• No concurrent phenytoin, phenobarbital, or other antiepileptic prophylaxis

• Concurrent bisphosphonates allowed for metastatic bone disease

Study Design

Primary Purpose: Treatment

Related Conditions & MeSH terms

• Neoplasm Metastasis
• Unspecified Adult Solid Tumor, Protocol Specific

Intervention

Biological:
• recombinant tissue plasminogen activator

Drug:
• captopril

Locations

Country	Name	City	State
United States	Robert H. Lurie Comprehensive Cancer Center at Northwestern University	Chicago	Illinois

Sponsors (2)

Lead Sponsor	Collaborator
Northwestern University	National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Angiostatin production			No